icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
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
CeYzeJjgpdkZWsQm